Functional role of inorganic trace elements in angiogenesis-Part II: Cr, Si, Zn, Cu, and S

Critical Reviews in Oncology/Hematology

Volumn 96, Issue 1, 2015, Pages 143-155

  Saghiri, Mohammad Ali ^a   Asatourian, Armen ^b   Orangi, Jafar ^b   Sorenson, Christine M ^a   Sheibani, Nader ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b Kamal Asgar Research Center   (Iran)

Author keywords

Angiogenesis; Endothelial cells; Trace elements; Wound healing

Indexed keywords

CHROMIUM; COPPER; SILICON; SULFUR; ZINC; TRACE ELEMENT;

ANGIOGENESIS; CARCINOGENESIS; CELL ADHESION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL GROWTH; CELL METABOLISM; CELL MIGRATION; CELL STRUCTURE; ENDOTHELIUM CELL; EXPOSURE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEALING; HOMEOSTASIS; HUMAN; NONHUMAN; REGENERATION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; ANIMAL; DRUG EFFECTS;

ANIMALS; CHROMIUM; COPPER; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; SILICON; SULFUR; TRACE ELEMENTS; ZINC;

EID: 84942200057     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.05.011     Document Type: Review

References (120)

1. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
2. Saghiri M.A., Asatourian A., Orangi J., Sorenson C.M., Sheibani N. Functional role of inorganic trace elements in angiogenesis Part I: (N, Fe, Se, P, Au, and Ca). Crit Rev Oncol/Hematol 2015. http://dx.doi.org/10.1016/j.critrevonc.2015.05.010.
3. Ducros V. Chromium metabolism. Biol Trace Elem Res 1992, 32:65-77.
4. Pechova A., Pavlata L. Chromium as an essential nutrient: a review. Vet Med 2007, 52:1-18.
5. Cohen M.D., Kargacin B., Klein C.B., Costa M. Mechanisms of chromium carcinogenicity and toxicity. CRC Crit Rev Toxicol 1993, 23:255-281.
6. Costa M. Toxicity and carcinogenicity of Cr(VI) in animal models and humans. CRC Crit Rev Toxicol 1997, 27:431-442.
7. De Flora S., Wetterhahn K. Mechanisms of chromium metabolism and genotoxicity. Life Chem Rep 1989, 7:169-244.
8. Sugiyama M. Role of physiological antioxidants in chromium(VI)-induced cellular injury. Free Radical Biol Med 1992, 12:397-407.
9. Luo H., Lu Y., Shi X., Mao Y., Dalal N.S. Chromium(IV)-mediated Fenton-like reaction causes DNA damage: implication to genotoxicity of chromate. Ann Clin Lab Sci 1996, 26:185-191.
10. Shi X., Mao Y., Knapton A.D., et al. Reaction of Cr(VI) with ascorbate and hydrogen peroxide generates hydroxyl radicals and causes DNA damage: role of a Cr(IV)-mediated Fenton-like reaction. Carcinogenesis 1994, 15:2475-2478.
11. Connett P.H., Wetterhahn K.E. Metabolism of the carcinogen chromate by cellular constituents. Struct Bond 1983, 54:93-124.
12. Kortenkamp A., Beyersmann D., O'Brien P. Uptake of chromium(III) complexes by erythrocytes. Toxicol Environ Chem 1987, 14:23-32.
13. Ye J., Zhang X., Young H.A., Mao Y., Shi X. Chromium(VI)-induced nuclear factor-k{cyrillic}B activation in intact cells via free radical reactions. Carcinogenesis 1995, 16:2401-2405.
14. Yao H., Guo L., Jiang B-H., Luo J., Shi X. Oxidative stress and chromium(VI) carcinogenesis. J Environ Pathol Toxicol Oncol 2008, 27:77-88.
15. Tully D.B., Collins B.J., Overstreet J.D., et al. Effects of arsenic, cadmium, chromium, and lead on gene expression regulated by a battery of 13 different promoters in recombinant HepG2 cells. Toxicol Appl Pharmacol 2000, 168:79-90.
16. Ding M., Shi X. Molecular mechanisms of Cr(VI)-induced carcinogenesis. Mol Cell Biochem 2002, 234:293-300.
17. Chen J., Zhao S., Nakada K., et al. Dominant-negative hypoxia-inducible factor-1α reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism. Am J Pathol 2003, 162:1283-1291.
18. Gao N., Jiang B-H., Leonard S.S., et al. p38 Signaling-mediated hypoxia-inducible factor 1α and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. J Biol Chem 2002, 277:45041-45048.
19. Qian Y., Jiang B.H., Flynn D.C., et al. Cr(VI) increases tyrosine phosphorylation through reactive oxygen species-mediated reactions. Mol Cell Biochem 2001, 222:199-204.
20. Ye J., Wang S., Leonard S.S., et al. Role of reactive oxygen species and p53 in chromium(VI)-induced apoptosis. J Biol Chem 1999, 274:34974-34980.
21. He J. Repression of miR-143/145 mediates chromium(VI)-induced cell transformation, tumor growth and tumor angiogenesis via IGF-IR/IRS1/ERK/IL-8. Toxicol Sci 2013, 134:26-38.
22. Pietak A.M., Reid J.W., Stott M.J., Sayer M. Silicon substitution in the calcium phosphate bioceramics. Biomaterials 2007, 28:4023-4032.
23. Li H., Chang J. Bioactive silicate materials stimulate angiogenesis in fibroblast and endothelial cell co-culture system through paracrine effect. Acta Biomater 2013, 9:6981-6991.
24. Zhai W., Lu H., Chen L., et al. Silicate bioceramics induce angiogenesis during bone regeneration. Acta Biomater 2012, 8:341-349.
25. Duan J., Yu Y., Li Y., Yu Y., Sun Z. Cardiovascular toxicity evaluation of silica nanoparticles in endothelial cells and zebrafish model. Biomaterials 2013, 34:5853-5862.
26. 4-nanoparticle induces hepatic and renal tissue injury via oxidative stress in mice. Int J Nanomed 2012, 7:4809.
27. Tzur-Balter A., Shatsberg Z., Beckerman M., Segal E., Artzi N. Mechanism of erosion of nanostructured porous silicon drug carriers in neoplastic tissues. Nat Commun 2015, 6:6208.
28. Day R.M., Boccaccini A.R., Shurey S., et al. Assessment of polyglycolic acid mesh and bioactive glass for soft-tissue engineering scaffolds. Biomaterials 2004, 25:5857-5866.
29. Keshaw H., Forbes A., Day R.M. Release of angiogenic growth factors from cells encapsulated in alginate beads with bioactive glass. Biomaterials 2005, 26:4171-4179.
30. Gorustovich A.A., Roether J.A., Boccaccini A.R. Effect of bioactive glasses on angiogenesis: a review of in vitro and in vivo evidences. Tissue Eng, B: Rev 2009, 16:199-207.
31. Alt V., Kögelmaier D.V., Lips K.S., et al. Assessment of angiogenesis in osseointegration of a silica-collagen biomaterial using 3D-nano-CT. Acta Biomater 2011, 7:3773-3779.
32. Hench L.L., Splinter R.J., Allen W., Greenlee T. Bonding mechanisms at the interface of ceramic prosthetic materials. J Biomed Mater Res 1971, 5:117-141.
33. Day R.M. Bioactive glass stimulates the secretion of angiogenic growth factors and angiogenesis in vitro. Tissue Eng 2005, 11:768-777.
34. Ghosh S.K., Nandi S.K., Kundu B., et al. In vivo response of porous hydroxyapatite and β-tricalcium phosphate prepared by aqueous solution combustion method and comparison with bioglass scaffolds. J Biomed Mater Res B: Appl Biomater 2008, 86:217-227.
35. Nandi S.K., Kundu B., Datta S., De D.K., Basu D. The repair of segmental bone defects with porous bioglass: an experimental study in goat. Res Vet Sci 2009, 86:162-173.
36. Yuan H., Yang Z., de Bruijn J.D., de Groot K., Zhang X. Material-dependent bone induction by calcium phosphate ceramics: a 2.5-year study in dog. Biomaterials 2001, 22:2617-2623.
37. Mahmood J., Takita H., Ojima Y., Kobayashi M., Kohgo T., Kuboki Y. Geometric effect of matrix upon cell differentiation: BMP-induced osteogenesis using a new bioglass with a feasible structure. J Biochem 2001, 129:163-171.
38. Kent Leach J., Kaigler D., Wang Z., Krebsbach P.H., Mooney D.J. Coating of VEGF-releasing scaffolds with bioactive glass for angiogenesis and bone regeneration. Biomaterials 2006, 27:3249-3255.
39. Aina V., Malavasi G., Fiorio Pla A., Munaron L., Morterra C. Zinc-containing bioactive glasses: surface reactivity and behaviour towards endothelial cells. Acta Biomater 2009, 5:1211-1222.
40. Coleman J.E. Zinc proteins: enzymes, storage proteins, transcription factors, and replication proteins. Annu Rev Biochem 1992, 61:897-946.
41. Berg J.M., Shi Y. The galvanization of biology: a growing appreciation for the roles of zinc. Science 1996, 271:1081-1085.
42. Prasad A.S. Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J Infect Dis 2000, 182:62-68.
43. Riordan J.F. Biochemistry of zinc. Med Clin North Am 1976, 60:661-674.
44. Ho E. Zinc deficiency, DNA damage and cancer risk. J Nutr Biochem 2004, 15:572-578.
45. Prasad A.S. Effects of zinc deficiency on Th1 and Th2 cytokine shifts. J Infect Dis 2000, 182. S62-S8.
46. Prasad A.S., Beck F.W., Doerr T.D., et al. Nutritional and zinc status of head and neck cancer patients: an interpretive review. J Am Coll Nutr 1998, 17:409-418.
47. Farrell N. Biomedical uses and applications of inorganic chemistry. An overview. Coord Chem Rev 2002, 232:1-4.
48. Schrauzer G. Trace elements in carcinogenesis. Adv Nutr Res 1979, 2:219-244.
49. Fong L.Y., Sivak A., Newberne P.M. Zinc deficiency and methylbenzylnitrosamine-induced esophageal cancer in rats. J Natl Cancer Inst 1978, 61:145-150.
50. Zowczak M., Iskra M., Torliński L., Cofta S. Analysis of serum copper and zinc concentrations in cancer patients. Biol Trace Elem Res 2001, 82:1-8.
51. Fong L.Y., Nguyen V.T., Farber J.L. Esophageal cancer prevention in zinc-deficient rats: rapid induction of apoptosis by replenishing zinc. J Natl Cancer Inst 2001, 93:1525-1533.
52. Boehm T., O'Reilly M.S., Keough K., Shiloach J., Shapiro R., Folkman J. Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem Biophys Res Commun 1998, 252:190-194.
53. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994, 265:346-355.
54. 2+ induced apoptosis in cancer cells. Free Radical Biol Med 2002, 32:431-445.
55. Hu Gf Copper stimulates proliferation of human endothelial cells under culture. J Cell Biochem 1998, 69:326-335.
56. Kaji T., Fujiwara Y., Yamamoto C., Sakamoto M., Kozuka H. Stimulation by zinc of cultured vascular endothelial cell proliferation: possible involvement of endogenous basic fibroblast growth factor. Life Sci 1994, 55:1781-1787.
57. Shian S-G., Kao Y-R., Wu F.Y-H., Wu C-W. Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram. Mol Pharmacol 2003, 64:1076-1084.
58. Marikovsky M., Nevo N., Vadai E., Harris-Cerruti C. Cu/Zn superoxide dismutase plays a role in angiogenesis. Int J Cancer 2002, 97:34-41.
59. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:721-732.
60. Sheffer M., Simon A.J., Jacob-Hirsch J., et al. Genome-wide analysis discloses reversal of the hypoxia-induced changes of gene expression in colon cancer cells by zinc supplementation. Oncotarget 2011, 2:1191-1202.
61. Nardinocchi L., Pantisano V., Puca R., et al. Zinc downregulates HIF-1α and inhibits its activity in tumor cells in vitro and in vivo. PLoS ONE 2010, 5:e15048.
62. Jackson K., Valentine R., Coneyworth L., Mathers J., Ford D. Mechanisms of mammalian zinc-regulated gene expression. Biochem Soc Trans 2008, 36:1262-1266.
63. Suh J., Rabson A.B. NF-κB activation in human prostate cancer: important mediator or epiphenomenon. J Cell Biochem 2004, 91:100-117.
64. Shukla S., MacLennan G.T., Marengo S.R., Resnick M.I., Gupta S. Constitutive activation of PI3K-Akt and NF-κB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005, 64:224-239.
65. Kim C.H., Kim J.H., Lee J., Hsu C.Y., Ahn Y.S. Thiol antioxidant reversal of pyrrolidine dithiocarbamate-induced reciprocal regulation of AP-1 and NF-κB. Biol Chem 2003, 384:143-150.
66. Galaris D., Evangelou A. The role of oxidative stress in mechanisms of metal-induced carcinogenesis. Crit Rev Oncol Hematol 2002, 42:93-103.
67. Uzzo R.G., Crispen P.L., Golovine K., Makhov P., Horwitz E.M., Kolenko V.M. Diverse effects of zinc on NF-κB and AP-1 transcription factors: implications for prostate cancer progression. Carcinogenesis 2006, 27:1980-1990.
68. Hellmuth M., Wetzler C., Nold M., et al. Expression of interleukin-8, heme oxygenase-1 and vascular endothelial growth factor in DLD-1 colon carcinoma cells exposed to pyrrolidine dithiocarbamate. Carcinogenesis 2002, 23:1273-1279.
69. Meerarani P., Reiterer G., Toborek M., Hennig B. Zinc modulates PPARγ signaling and activation of porcine endothelial cells. J Nutr 2003, 133:3058-3064.
70. Goodman V., Brewer G., Merajver S. Copper deficiency as an anti-cancer strategy. Endocr Relat Cancer 2004, 11:255-263.
71. Nasulewicz A., Mazur A., Opolski A. Role of copper in tumour angiogenesis-clinical implications. J Trace Elem Med Biol 2004, 18:1-8.
72. McAuslan B., Reilly W., Hannan G., Gole G. Angiogenic factors and their assay: activity of formyl methionyl leucyl phenylalanine, adenosine diphosphate, heparin, copper, and bovine endothelium stimulating factor. Microvasc Res 1983, 26:323-338.
73. McAuslan B., Reilly W. Endothelial cell phagokinesis in response to specific metal ions. Exp Cell Res 1980, 130:147-157.
74. Li S., Wang M., Chen X., Li S.F., Li-Ling J., Xie H.Q. Inhibition of osteogenic differentiation of mesenchymal stem cells by copper supplementation. Cell Prolif 2014, 47:81-90.
75. McAuslan B., Gole G. Cellular and molecular mechanisms in angiogenesis. Trans Ophthalmol Soc UK 1980, 100:354-358.
76. Li Q-f, Ding X-q, Kang Y.J. Copper promotion of angiogenesis in isolated rat aortic ring: role of vascular endothelial growth factor. J Nutr Biochem 2014, 25:44-49.
77. Hoffman H., McAuslan B., Robertson D., Burnett E. An endothelial growth-stimulating factor from salivary glands. Exp Cell Res 1976, 102:269-275.
78. Raju K.S., Alessandri G., Ziche M., Gullino P.M. Ceruloplasmin, copper ions, and angiogenesis. J Natl Cancer Inst 1982, 69:1183-1188.
79. Gullino P.M. Microenvironment and angiogenic response. Angiogenesis 1992, 61:125-128.
80. Senra Varela A., Lopez Saez J., Quintela Senra D. Serum ceruloplasmin as a diagnostic marker of cancer. Cancer Lett 1997, 121:139-145.
81. Yoshida D., Ikeda Y., Nakazawa S. Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors. J Neurooncol 1993, 16:109-115.
82. Gupta S.K., Shukla V.K., Vaidya M.P., Roy S.K., Gupta S. Serum trace elements and Cu/Zn ratio in breast cancer patients. J Surg Oncol 1991, 46:178-181.
83. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control 1999, 6:438-448.
84. Pan Q., Kleer C.G., van Golen K.L., et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002, 62:4854-4859.
85. Mamou F., May K.S., Schiepper M.J., et al. Tetrathiomolybdate blocks bFGF-but not VEGF-induced incipient angiogenesis in vitro. Anticancer Res 2006, 26:1753-1758.
86. Gérard C., Bordeleau L-J., Barralet J., Doillon C.J. The stimulation of angiogenesis and collagen deposition by copper. Biomaterials 2010, 31:824-831.
87. Yang S.J., Uriu-Adams J.Y., Keen C.L., Rucker R.B., Lanoue L. Effects of copper deficiency on mouse yolk sac vasculature and expression of angiogenic mediators. Birth Defects Res B: Dev Reprod Toxicol 2006, 77:445-454.
88. Gopal A., Kant V., Gopalakrishnan A., Tandan S.K., Kumar D. Chitosan-based copper nanocomposite accelerates healing in excision wound model in rats. Eur J Pharmacol 2014, 731:8-19.
89. Rahman K. Historical perspective on garlic and cardiovascular disease. J Nutr 2001, 131:977-979.
90. Milner J.A. Mechanisms by which garlic and allyl sulfur compounds suppress carcinogen bioactivation. Adv Exp Med Biol 2001, 492:69-81.
91. Powolny A.A., Singh S.V. Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett 2008, 269:305-314.
92. Sundaram S.G., Milner J.A. Diallyl disulfide induces apoptosis of human colon tumor cells. Carcinogenesis 1996, 17:669-673.
93. Mousa A.S., Mousa S.A. Anti-angiogenesis efficacy of the garlic ingredient alliin and antioxidants: role of nitric oxide and p53. Nutr Cancer 2005, 53:104-110.
94. Yi L., Su Q. Molecular mechanisms for the anti-cancer effects of diallyl disulfide. Food Chem Toxicol 2013, 57:362-370.
95. Xiao D., Li M., Herman-Antosiewicz A., et al. Diallyl trisulfide inhibits angiogenic features of human umbilical vein endothelial cells by causing Akt inactivation and down-regulation of VEGF and VEGF-R2. Nutr Cancer 2006, 55:94-107.
96. Meyer K., Ueberham E., Gebhardt R. Influence of organosulphur compounds from garlic on the secretion of matrix metalloproteinases and their inhibitor TIMP-1 by cultured HUVEC cells. Cell Biol Toxicol 2004, 20:253-260.
97. Cai W-J., Wang M-J., Moore P.K., Jin H-M., Yao T., Zhu Y-C. The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc Res 2007, 76:29-40.
98. Papapetropoulos A., Pyriochou A., Altaany Z., et al. Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci USA 2009, 106:21972-21977.
99. Papapetropoulos A., García-Cardeña G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997, 100:3131.
100. Yang G., Wu L., Jiang B., et al. H2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ-lyase. Science 2008, 322:587-590.
101. Zhao K., Ju Y., Li S., Al Tanny Z., Wang R., Yang G. S-sulfhydration of MEK1 leads to PARP-1 activation and DNA damage repair. EMBO Rep 2014, 15:792-800.
102. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 2012, 92:791-896.
103. Jiang B., Tang G., Cao K., Wu L., Wang R. Molecular mechanism for H2S-induced activation of KATP channels. Antioxid Redox Signal 2010, 12:1167-1178.
104. Szabó C., Papapetropoulos A. Hydrogen sulphide and angiogenesis: mechanisms and applications. Br J Pharmacol 2011, 164:853-865.
105. Foxall C., Wei Z., Schaefer M.E., et al. Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation. J Cell Physiol 1996, 168:657-667.
106. Imamura T., Mitsui Y. Heparan sulfate and heparin as a potentiator or a suppressor of growth of normal and transformed vascular endothelial cells. Exp Cell Res 1987, 172:92-100.
107. Yamamoto I., Takahashi M., Suzuki T., Seino H., Mori H. Antitumor effect of seaweeds. IV. Enhancement of antitumor activity by sulfation of a crude fucoidan fraction from Sargassum kjellmanianum. Jpn J Exp Med 1984, 54:143-151.
108. Coombe D.R., Parish C.R., Ramshaw I.A., Snowden J.M. Analysis of the inhibition of tumour metastasis by sulphated polysaccharides. Int J Cancer 1987, 39:82-88.
109. Soeda S., Kozako T., Iwata K., Shimeno H. Oversulfated fucoidan inhibits the basic fibroblast growth factor-induced tube formation by human umbilical vein endothelial cells: its possible mechanism of action. Biochim Biophys Acta 2000, 1497:127-134.
110. Soeda S., Shibata Y., Shimeno H. Inhibitory effect of oversulfated fucoidan on tube formation by human vascular endothelial cells. Biol Pharm Bull 1997, 20:1131-1135.
111. Koyanagi S., Tanigawa N., Nakagawa H., Soeda S., Shimeno H. Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Biochem Pharmacol 2003, 65:173-179.
112. Higdon J.V., Delage B., Williams D.E., Dashwood R.H. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res 2007, 55:224-236.
113. Gamet-Payrastre L., Li P., Lumeau S., et al. Sulforaphane, a naturally occurring isothiocyanate, induces cell cycle arrest and apoptosis in HT29 human colon cancer cells. Cancer Res 2000, 60:1426-1433.
114. Yuan F., Chen D., Liu K., Sepkovic D., Bradlow H., Auborn K. Anti-estrogenic activities of indole-3-carbinol in cervical cells: implication for prevention of cervical cancer. Anticancer Res 1998, 19:1673-1680.
115. Dalessandri K.M., Firestone G.L., Fitch M.D., Bradlow H.L., Bjeldanes L.F. Pilot study: effect of 3,3'-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer 2004, 50:161-167.
116. Iozzo R.V., Sanderson R.D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med 2011, 15:1013-1031.
117. Raman K., Kuberan B. Chemical tumor biology of heparan sulfate proteoglycans. Curr Chem Biol 2010, 4:20.
118. Nakato H., Kimata K. Heparan sulfate fine structure and specificity of proteoglycan functions. Biochim Biophys Acta 2002, 1573:312-318.
119. Raman K., Karuturi R., Swarup V.P., Desai U.R., Kuberan B. Discovery of novel sulfonated small molecules that inhibit vascular tube formation. Bioorg Med Chem Lett 2012, 22:4467-4470.
120. Raman K., Kuberan B. Differential effects of Heparitinase I and Heparitinase III on endothelial tube formation in vitro. Biochem Biophys Res Commun 2010, 398:191-193.